Pharmaceuticals · NYSE
LLYELI LILLY & Co
- Last close
- $1,443.50 +1.1%
- 52-week range
- $850.51 to $1,460.00
- Market cap
- $1.36T
- Next earnings
- Not scheduled
Fiscal 2025 at a glance
Stock price
Valuation vs its own 10 years
Above its 10-year median on all 4 multiples
Where each multiple sits today inside its own range since 2016, measured at every quarter end. The thin tick is the median.
Key statistics
Trailing 12 months unless noted, through the quarter ending 2026-09-30. Every figure carries its unit.
Valuation
- P/E
- 46.8x
- Earnings yield
- 2.1%
- Price / sales
- 15.7x
- Price / book
- 33.7x
- Price / operating cash flow
- 44.3x
- EV / EBITDA
- 37.7x
- EV / sales
- 16.2x
- Free cash flow yield
- 1.4%
Profitability
- Gross margin
- 83.6%
- Operating margin
- n/a
- Net margin
- 31.9%
- Return on equity
- 68.5%
- Return on capital
- n/a
n/a: Not reported
Growth per year
- Revenue, 3 years
- +31.7%
- Revenue, 5 years
- +21.6%
- Revenue, 9 years
- +15.1%
- EPS, 3 years
- +49.3%
Balance sheet
- Cash and investments
- $4.88B
- Total debt
- $49.5B
- Net cash
- -$44.6B
- Debt / equity
- 1.23x
- Current ratio
- 1.39x
Shares and dividend
- Shares outstanding
- 941M
- Share count, 5 years
- -1.4%
- Beta, 1 year
- 0.30
- Dividend yield
- n/a
- Dividend per share, TTM
- n/a
- Payout ratio
- 21.7%
n/a: No dividend
Ten years of the business
Last 40 quarters, fiscal 2016 to 2025 and after. Hover a bar for its quarter.
Fiscal years 2016 to 2025.
Where the revenue comes from
Product went from 89% to 94% of revenue in 3 years
Share of revenue by product line, fiscal 2022 to 2025, as reported in the 10-K.
| Product line | Revenue | Share | vs FY24 |
|---|---|---|---|
| Product | $61.0B | 93.5% | +50% |
| Collaboration and Other Revenue | $4.22B | 6.5% | -2% |
Pharmaceuticals peers
The largest names in the same industry that we cover, all in US dollars. The last column applies the same history test to each peer.
| Company | Market cap | Revenue growth | Operating margin | P/E | P/S | P/E vs own history |
|---|---|---|---|---|---|---|
| LLY ELI LILLY & Co | $1.36T | +46% | n/a | 46.8x | 15.7x | 60th percentile |
| JNJ Johnson & Johnson | $688B | +8% | n/a | 43.4x | 6.9x | 90th percentile |
| MRK Merck & Co., Inc. | $364B | +5% | n/a | 152x | 5.4x | 98th percentile |
| PFE Pfizer Inc | $165B | +1% | n/a | 41.2x | 2.6x | 97th percentile |
| BMY Bristol Myers Squibb Co | $130B | +4% | n/a | 14.1x | 2.6x | 13th percentile |
| TEVA Teva Pharmaceutical Industries Ltd | $51.9B | -16% | 10.2% | 103x | 3.7x | Not enough history |
The company
- Sector
- Health Care
- Industry
- Pharmaceuticals
- CEO
- David A. Ricks
- Employees
- 38,350 (as of 2018)
- Founded
- 1875
- Headquarters
- Indianapolis, IN
- Fiscal year ends
- December
- Website
- lilly.com
What it does
Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 36 countries. Its products are marketed in approximately 90 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.
Description from Wikipedia (CC BY-SA).
Around the numbers
What the rest of EdgeStacker knows about LLY.